Aldeyra Therapeutics, Inc. (ALDX)
$1.51-$0.03 (-1.95%) Today
Richard Douglas
Stephen Machatha - OfficerAldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 1 | 250,000 | $418K |
| Grant or award | 17 | 567,403 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
18 Form 4 filings on record, the earliest from Oct 21, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Nancy Miller-Rich | Grant or award | Stock Option (Right to Buy) | 70,000 | $0.00 | - | |
| Nancy Miller-Rich | Grant or award | Stock Option (Right to Buy) | 3,318 | $0.00 | - | |
| Richard Douglas | Grant or award | Stock Option (Right to Buy) | 70,000 | $0.00 | - | |
| Richard Douglas | Grant or award | Stock Option (Right to Buy) | 19,909 | $0.00 | - | |
| Richard Douglas | Grant or award | Stock Option (Right to Buy) | 2,323 | $0.00 | - | |
| Gary M. Phillips | Grant or award | Stock Option (Right to Buy) | 70,000 | $0.00 | - | |
| Gary M. Phillips | Grant or award | Stock Option (Right to Buy) | 6,636 | $0.00 | - | |
| Gary M. Phillips | Grant or award | Stock Option (Right to Buy) | 4,977 | $0.00 | - | |
| William D. Clark | Grant or award | Stock Option (Right to Buy) | 70,000 | $0.00 | - | |
| William D. Clark | Grant or award | Stock Option (Right to Buy) | 2,323 | $0.00 | - | |
 Neal Walker | Grant or award | Stock Option (Right to Buy) | 70,000 | $0.00 | - | |
| Neal Walker | Grant or award | Stock Option (Right to Buy) | 3,318 | $0.00 | - | |
| Ben Bronstein | Grant or award | Stock Option (Right to Buy) | 5,309 | $0.00 | - | |
| Ben Bronstein | Grant or award | Stock Option (Right to Buy) | 4,977 | $0.00 | - | |
| Ben Bronstein | Grant or award | Stock Option (Right to Buy) | 70,000 | $0.00 | - | |
| Darlene M. Deptula-Hicks | Grant or award | Stock Option (Right to Buy) | 84,557 | $0.00 | - | |
| Darlene M. Deptula-Hicks | Grant or award | Stock Option (Right to Buy) | 9,756 | $0.00 | - | |
| Todd C. Brady - Officer | Open-market purchase | Common Stock | 250,000 | $1.67 | $418K | |
| Todd C. Brady - Officer | Grant or award | Stock Option (right to buy) | 1,880,510 | $0.00 | - | |
| Todd C. Brady - Officer | Grant or award | Bonus Units | 632,318 | $0.00 | - | |
| Richard Douglas | Open-market purchase | Common Stock | 70,000 | $1.40 | $98K | |
| Michael Alfieri - Officer | Open-market purchase | Common Stock | 5,000 | $1.42 | $7K | |
| Michael Alfieri - Officer | Open-market purchase | Common Stock | 2,500 | $5.30 | $13K | |
| Stephen Machatha - Officer | Open-market sale | Common Stock | 22,073 | $5.15 | $114K | |
| Martin Joseph Joyce | Grant or award | Stock Option (Right to Buy) | 62,728 | $0.00 | - | |
| Martin Joseph Joyce | Grant or award | Stock Option (Right to Buy) | 1,689 | $0.00 | - | |
| Martin Joseph Joyce | Grant or award | Stock Option (Right to Buy) | 7,238 | $0.00 | - | |
| Gary M. Phillips | Grant or award | Stock Option (Right to Buy) | 62,728 | $0.00 | - | |
| Gary M. Phillips | Grant or award | Stock Option (Right to Buy) | 4,825 | $0.00 | - | |
| Gary M. Phillips | Grant or award | Stock Option (Right to Buy) | 3,619 | $0.00 | - | |
| Richard Douglas | Grant or award | Stock Option (Right to Buy) | 62,728 | $0.00 | - | |
| Richard Douglas | Grant or award | Stock Option (Right to Buy) | 14,476 | $0.00 | - | |
| Richard Douglas | Grant or award | Stock Option (Right to Buy) | 1,689 | $0.00 | - | |
| PERCEPTIVE ADVISORS LLC - 10% Owner | Open-market sale | Common Stock | 3,400,000 | $1.42 | $4.83M | |
| Nancy Miller-Rich | Open-market purchase | Common Stock | 413 | $12.81 | $5K | |
| Nancy Miller-Rich | Open-market purchase | Common Stock | 509 | $10.13 | $5K |
Aldeyra Therapeutics, Inc. (ALDX) had 8 insider filings in the last 90 days, with the most recent on 2026-06-11. The full record for ALDX runs to 18 Form 4 filings, the earliest from 2024-10-21. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
1 insider purchase of ALDX was filed in the last 90 days, totaling $418K.
No insider sales of ALDX were filed in the last 90 days. 2 sales are on record for this company.
This page tracks ALDX Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add ALDX to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
